Published Case Report Demonstrates the Clinical Utility of Biocept's CTC Platform in the Management of Patients with Metastatic Breast Cancer
The article, "Clinical utility of Target Selector™ circulating tumor cell (CTC) testing in tumor marker gene amplification and protein expression in metastatic breast cancer management," was published in the
"Determining the biomarker status of patients with breast cancer is paramount for selecting appropriate targeted therapy that can significantly improve treatment outcomes," said
"We continue to expand the body of clinical evidence supporting the use of our Target Selector™ platform with our third published case report in 2018," said
About
Choosing the most effective treatment for women with recurrent or newly diagnosed metastatic breast cancer depends on ER, PR and HER2 receptor status. These key targets help doctors understand which therapies are most appropriate for patient treatment, and can also be used to help breast cancer patients qualify for clinical trials. Despite benefits to patient survival, molecular biomarker data is often difficult to obtain in metastatic settings due to patients' health status, a refusal to undergo another biopsy, or the tumor is metastasized to a difficult-to-sample region of the body such as bone, brain or the lungs. Additionally, tissue molecular analyses may be inconclusive due to insufficient tissue amounts from biopsies or interference of bone tissue decalcification procedures with immuno-histochemical stains. The recent development Target Selector liquid biopsy from
For more information on
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the outcomes of patients diagnosed with cancer, our ability to increase physician adoption of our Target Selector assays, and whether additional case studies will be published in the future supporting the use of our liquid biopsy platform, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our
View original content with multimedia:http://www.prnewswire.com/news-releases/published-case-report-demonstrates-the-clinical-utility-of-biocepts-ctc-platform-in-the-management-of-patients-with-metastatic-breast-cancer-300666664.html
SOURCE
Trevelino/Keller, Colleen Murphy, cmurphy@trevelinokeller.com, 404-214-0722, Ext. 109 Investor Contact: LHA Investor Relations, Jody Cain, Jcain@lhai.com, 310-691-7100